Ophthalmology Management - June 2024

PART C MEDICARE VS TRADITIONAL MEDICARE

BRANDY H. SPERRY 2024-05-15 09:06:18

We can expect enrollment in Medicare Part C, or Medicare Advantage (MA), to continue its two-decade long trend of growth. According to the Kaiser Family Foundation (KFF), MA enrollment in 2023 was 30.8 million or 51% of eligible beneficiaries. The Congressional Budget Office estimates that enrollment will rise to about 61% of eligible beneficiaries by 2032;2 the growth can be attributed to the strong financial incentives Congress created for plans in the Medicare Modernization Act of 2003. In 2023, more beneficiaries elected MA plans instead of traditional Medicare, with significant ramifications for providers.

Of note, the reimbursement and covered services for MA plans can be different from Medicare Part B plans. This article helps to outline the difference between the two programs and hopefully help your practice decrease the administrative burden of insufficient claims.


Brandy H. Sperry, COMT, COE, CPC, CPMA, is an associate consultant for Corcoran Consulting Group, which specializes in coding and reimbursement issues for ophthalmology and optometry practices. Contact her at bsperry@corcoranccg.com or at 800-399-6565, ext 238.


A LITTLE BACKGROUND
Medicare Part C, or Medicare Advantage, are health plans offered by private companies approved by Medicare. These plans provide all the Part A (Hospital Insurance) and Part B (Medical Insurance) coverage and may offer extra coverage, with additional benefits and services that traditional Medicare does not cover, such as:

• Routine dental exams, cleanings, X-rays and dentures

• Hearing aid exam, hearing aid fitting and a discount on hearing aids

• Routine vision exam and an allowance for eyeglasses and contact lenses

• Emergency medical assistance while traveling outside the United States

• Fitness memberships

• An allowance to buy health-care products.

These plans frequently include Part D prescription drug coverage with no or low copays. MA plans are heavily promoted to Medicare beneficiaries, while ordinary or Part A/B Medicare is not promoted, so many beneficiaries assume these MA plans are their best option.

According to KFF, “The share of Medicare beneficiaries enrolled in Medicare Advantage varies widely across counties. In 2023, nearly one-third (31%) of Medicare beneficiaries live in a county where at least 60% of all Medicare beneficiaries are enrolled in Medicare Advantage plans, while 10% live in a county where less than one-third of all Medicare beneficiaries are enrolled in Medicare Advantage plans.”

A few firms dominate MA plans. A KFF analysis found that United- Healthcare and Humana make up fully 47% of all Medicare Advantage enrollees. Moreover, “ in nearly a third of counties (32%; or 1,013 counties), these two firms account for at least 75% of Medicare Advantage enrollment.” The financial rewards to the payor are substantial. Payments to MA plans are higher than traditional Medicare for several reasons, including bonuses, rebates and risk adjustments. 3 Not surprisingly, this has led to substantial profits as demonstrated by UnitedHealth Group extending its streak as the most profitable company among major national insurers in the first quarter of 2023, reporting $5.6 billion in earnings.

PART C AND PROVIDERS
The story is different for providers. MA plans may set their own payment rates; they don’t have to follow the Medicare Physician Fee Schedule.

Based on a study published in JAMA Internal Medicine, “Physician reimbursement in MA is more strongly tied to traditional Medicare than to commercial prices, but MA plans take advantage of favorable commercial prices for services for which traditional Medicare overpays.”

A CMS booklet for beneficiaries says, “Each Medicare Advantage Plan can charge different out-of-pocket costs and have different rules for how you get services (like whether you need a referral to see a specialist or if you have to go to only doctors, facilities, or suppliers that belong to the plan for nonemergency or non-urgent care). These rules can change each year.”

Significantly, MA plans have their own policies for processing claims for reimbursement. Covered diagnoses vary from traditional Medicare. For some services, prior authorizations may be required, which is not typically the case for Part B Medicare. CMS prohibits MA plans from using the Advance Beneficiary Notice of Noncoverage, or ABN; instead, predetermination of benefits by the provider or beneficiary is the method used when coverage is in doubt.

MA plans feature a wide variety of offerings. Some cap out-of-pocket beneficiary expenditures on an annual basis for covered services, while Part B Medicare does not.

KEY ADMINISTRATIVE PRACTICES
Our experience with claims for reimbursement with MA plans is very different from traditional Medicare. Assessing coverage is more difficult; denied claims are not easily addressed; administration is frequently more time consuming; maintaining preferred provider status can be challenging; contracting requires serious effort and creativity. Administrators or practice managers should:

• Devote significant effort to contracts and negotiations with MA plans

• Collect and analyze outcomes data to demonstrate quality of care

• Establish administrative processes consistent with MA plan requirements.

KEEP A WATCHFUL EYE ON MA PLANS
Enrollment in MA plans continues to increase with significant implications for providers. These plans use different administrative processes than traditional Medicare and may have lower payment rates. MA plans generate surprises for billers such as coverage of routine eye exams and refractions. Access to beneficiaries depends on retention of your physicians on MA panels of preferred providers. As enrollments of Medicare beneficiaries shift away from traditional Medicare toward MA plans, time and attention needs to be devoted to this strategic change.

For references see the online version of this article.

©BROADCASTMED LLC. View All Articles.

PART C MEDICARE VS TRADITIONAL MEDICARE
https://digital.ophthalmologymanagement.com/articles/part-c-medicare-vs-traditional-medicare

Menu
  • Page View
  • Contents View
  • Advertisers
  • Website

Issue List

OphthalmicASC March 2026

November 2025

Glaucoma Physician November 2025

OphthalmicASC October 2025

October 2025

September 2025

Glaucoma Physician September 2025

OphthalmicASC July 2025

July/August 2025

June 2025

OphthalmicASC May 2025

May 2025

April 2025

March 2025

OphthalmicASC February 2025

January/February 2025

Nov/Dec 2024 Galucoma Supplement

November/December 2024

October 2024

The OphthalmicASC October 2024

September 2024

August 2024

The OphthalmicASC August 2024

July 2024

Mededicus supplement 2024

July Alcon Vision Suite onsert

Alcon Vision Suite Onsert 2024

Women in Glaucoma Supplement 2024

June 2024

May 2024

The OphthalmicASC May 2024

Ryzumvi OMD 2024

April 2024

March 2024

Meibo Supplement March 2024

January/February 2024

The OphthalmicASC February 2024

December 2023

November 2023

2023 Glaukos Migs supplement

A New Day for Geographic Atrophy (GA) - October 2023

October 2023

The Ophthalmic ASC October 2023

September 2023

August 2023

Ophthalmic ASC Supplement August 2023

Alcon IOL Broadcast July/August 2023

July 2023

July 2023

June 2023

May 2023

The Ophthalmic ASC May 2023

April 2023

March 2023

The Ophthalmic ASC February 2023

February 2023

January 2023

January 2023 - Ocular Therapeutix Supplement

2022 40 Under 40 Supplement

December 2022

Dry Eye Beast November 2022

November 2022

October 2022

The Ophthalmic ASC October 2022

September 2022

August 2022

The Ophthalmic ASC August 2022

July 2022

June 2022

May 2022

May 2022 - Ophthalmic ASC

April 2022

March 2022

Surgeon's Choice Supplement

ZEISS Cataract Workflow Technologies February 2022

February 2022

OASC February 2022

January 2022

Kala Best Of December 2021

December 2021

November 2021

Vyzulta November 2021

Eyepoint Supplement October 2021

October 2021

OASC October 2021

Bausch Vyzulta October 2021

September 2021

Bausch Supplement September 2021

August 2021

OASC August 2021

July 2021

June 2021

May 2021

Vyzulta May 2021

OASC May 2021

April 2021

March 2021

Prolensa January 2021

OASC February 2021

February 2021

January 2021

December 2020

The Crossroads of Glaucoma and Ocular Surface Disease

November 2020

October 2020

OASC October 2020

EyePoint DEXYCU® September 2020

September 2020

OASC August 2020

Real-world Experiences With the PanOptix® Trifocal IOL

August 2020

July 2020

June 2020

May 2020

OASC May 2020

April 2020

Corneal Physician April 2020

Dry Eye Recap March 2020

Glaukos iStent Recap March 2020

March 2020

February 2020

iVista CME January 2020

January 2020

December 2019

November 2019

EyePoint Corporate Profile

DEXYCU Product Profile October 2019

October 2019

OASC October 2019

Alcon RESTOR Supplement Part 7

ASCRS Panel Discussion Recap Oct 2019

Alcon RESTOR Supplement Part 6

Dry Eye Update September 2019

September 2019

Alcon RESTOR Supplement Part 5

August 2019

Alcon RESTOR Supplement Part 4

OASC August 2019

Alcon RESTOR Supplement Part 2

Alcon RESTOR Supplement Part 3

Alcon NGENUITY Supplement Part 1

July 2019

Alcon RESTOR Supplement Part 1

June 2019

ZEISS Supplement June 2019

B+L Vyzulta Supplement

May 2019

OASC May 2019

April 2019

March 2019

OASC February 2019

Dry Eye Practice March 2019

Alcon Activate February 2019

February 2019

January 2019

December 2018

Glaucoma Physician December 2018

Alcon Activate November/December 2018

November 2018

Modernizing Medicine Supplement

October 2018

OASC October 2018

September 2018

Alcon Supplement October 2018

Glaucoma Physician September 2018

August 2018

OASC August 2018

July 2018

Glaucoma Physician June 2018

Ophthalmic Instrument Catalog

June 2018

CareCredit May 2018

May 2018

OASC May 2018

April 2018

BioTissue April 2018

Glaucoma Physican March 2018

Dry Eye Center of Excellence March 2018

February 2018

OASC February 2018

CareCredit February 2018


Library